Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126337301 | 12633730 | 1 | I | 20160726 | 20160809 | 20160809 | EXP | US-ENDO PHARMACEUTICALS INC-2016-004779 | ENDO | WALLACE K, FILIPEK R, LA HOZ R. SUBTHERAPEUTIC VORICONAZOLE CONCENTRATIONS ASSOCIATED WITH CONCOMITANT DEXAMETHASONE: CASE REPORT AND REVIEW OF THE LITERATURE. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016 AUG;41:441-443. | 84.00 | YR | M | Y | 60.00000 | KG | 20160809 | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126337301 | 12633730 | 1 | PS | DEXAMETHASONE ELIXIR | DEXAMETHASONE | 1 | Oral | Y | 91188 | 4 | MG | UNKNOWN | Q8H | ||||||
| 126337301 | 12633730 | 2 | SS | DEXAMETHASONE ELIXIR | DEXAMETHASONE | 1 | Oral | Y | 91188 | 4 | MG | UNKNOWN | Q8H | ||||||
| 126337301 | 12633730 | 3 | SS | DEXAMETHASONE ELIXIR | DEXAMETHASONE | 1 | Oral | Y | 91188 | 3 | MG | UNKNOWN | Q8H | ||||||
| 126337301 | 12633730 | 4 | SS | DEXAMETHASONE ELIXIR | DEXAMETHASONE | 1 | Oral | Y | 91188 | 2 | MG | UNKNOWN | Q8H | ||||||
| 126337301 | 12633730 | 5 | SS | DEXAMETHASONE ELIXIR | DEXAMETHASONE | 1 | Oral | Y | 91188 | 1 | MG | UNKNOWN | Q8H | ||||||
| 126337301 | 12633730 | 6 | SS | DEXAMETHASONE ELIXIR | DEXAMETHASONE | 1 | Oral | Y | 91188 | .5 | MG | UNKNOWN | Q8H | ||||||
| 126337301 | 12633730 | 7 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 6 MG/KG (400 MG) TIMES TWO DOSES | 0 | 400 | MG | UNKNOWN | Q12H | ||||||
| 126337301 | 12633730 | 8 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 4 MG/KG (250 MG) FOR ONE WEEK | 0 | 250 | MG | UNKNOWN | Q12H | ||||||
| 126337301 | 12633730 | 9 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 0 | 200 | MG | UNKNOWN | Q12H | |||||||
| 126337301 | 12633730 | 10 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 0 | UNKNOWN | ||||||||||
| 126337301 | 12633730 | 11 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 0 | 250 | MG | UNKNOWN | Q12H | |||||||
| 126337301 | 12633730 | 12 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 0 | UNKNOWN | ||||||||||
| 126337301 | 12633730 | 13 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 0 | 300 | MG | UNKNOWN | Q12H | |||||||
| 126337301 | 12633730 | 14 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 0 | 300 | MG | UNKNOWN | Q12H |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126337301 | 12633730 | 1 | Brain oedema |
| 126337301 | 12633730 | 7 | Brain abscess |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126337301 | 12633730 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126337301 | 12633730 | Drug level below therapeutic | |
| 126337301 | 12633730 | Inhibitory drug interaction |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |